Stocktoria
Vera Therapeutics, Inc. VERA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-05-14
Chart by TradingView
1/9
Piotroski F — financial health
4.64
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$315.5M | -$167.2M | -$102.0M | -$90.9M | -$34.4M |
| Net income | -$299.6M | -$152.1M | -$96.0M | -$89.1M | -$32.6M |
| Operating cash flow | -$241.1M | -$134.7M | -$92.2M | -$67.6M | -$23.7M |
| Free cash flow | -$241.7M | -$135.7M | -$92.2M | -$67.7M | -$23.7M |
| Total assets | $734.7M | $655.7M | $175.5M | $131.4M | $83.7M |
| Total liabilities | $130.2M | $78.5M | $73.9M | $54.5M | $14.2M |
| Shareholders' equity | $604.5M | $577.2M | $101.7M | $76.9M | $69.6M |
| Ratios | |||||
| Return on assets | -40.8% | -23.2% | -54.7% | -67.8% | -38.9% |
| Return on equity | -49.6% | -26.4% | -94.4% | -115.8% | -46.9% |
| Debt / equity | 0.12× | 0.09× | 0.49× | 0.32× | 0.07× |
| Current ratio | 13.64 | 25.67 | 7.71 | 4.91 | 10.73 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,228,525 | $49.4M |
| RENAISSANCE TECHNOLOGIES LLC | 457,300 | $18.4M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.64 (safe)
- Working capital / assets 0.919
- Retained earnings / assets -1.036
- EBIT / assets -0.429
- Equity / liabilities 4.643
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001831828 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.